CN113480666B - Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 - Google Patents
Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 Download PDFInfo
- Publication number
- CN113480666B CN113480666B CN202110929276.8A CN202110929276A CN113480666B CN 113480666 B CN113480666 B CN 113480666B CN 202110929276 A CN202110929276 A CN 202110929276A CN 113480666 B CN113480666 B CN 113480666B
- Authority
- CN
- China
- Prior art keywords
- protein
- fusion protein
- polypeptide
- expression
- signal peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102000037865 fusion proteins Human genes 0.000 title claims abstract description 45
- 108020001507 fusion proteins Proteins 0.000 title claims abstract description 45
- 238000003908 quality control method Methods 0.000 title claims abstract description 11
- 238000001514 detection method Methods 0.000 title abstract description 10
- 238000002360 preparation method Methods 0.000 title abstract description 9
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 39
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 30
- 229920001184 polypeptide Polymers 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 28
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 28
- 230000014509 gene expression Effects 0.000 claims abstract description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 claims abstract description 16
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims abstract description 14
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims abstract description 14
- 230000003252 repetitive effect Effects 0.000 claims abstract description 5
- 239000013604 expression vector Substances 0.000 claims description 8
- 238000003306 harvesting Methods 0.000 claims description 8
- 239000012634 fragment Substances 0.000 claims description 7
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 6
- 238000012258 culturing Methods 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 abstract description 14
- 239000006228 supernatant Substances 0.000 abstract description 11
- 239000000047 product Substances 0.000 abstract description 9
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 101100314454 Caenorhabditis elegans tra-1 gene Proteins 0.000 abstract description 2
- 210000004027 cell Anatomy 0.000 description 38
- 239000000243 solution Substances 0.000 description 14
- 238000000034 method Methods 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 102100034256 Mucin-1 Human genes 0.000 description 9
- 108010008707 Mucin-1 Proteins 0.000 description 7
- 238000004113 cell culture Methods 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 238000001890 transfection Methods 0.000 description 6
- 239000013613 expression plasmid Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000011084 recovery Methods 0.000 description 5
- 230000010473 stable expression Effects 0.000 description 5
- 230000010474 transient expression Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 4
- 230000006801 homologous recombination Effects 0.000 description 4
- 238000002744 homologous recombination Methods 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 229930027917 kanamycin Natural products 0.000 description 3
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 3
- 229960000318 kanamycin Drugs 0.000 description 3
- 229930182823 kanamycin A Natural products 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 101001133056 Homo sapiens Mucin-1 Proteins 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000013595 glycosylation Effects 0.000 description 2
- 238000006206 glycosylation reaction Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 230000001052 transient effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- YYSWCHMLFJLLBJ-ZLUOBGJFSA-N Ala-Ala-Ser Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(O)=O YYSWCHMLFJLLBJ-ZLUOBGJFSA-N 0.000 description 1
- FQNILRVJOJBFFC-FXQIFTODSA-N Ala-Pro-Asp Chemical compound C[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CC(=O)O)C(=O)O)N FQNILRVJOJBFFC-FXQIFTODSA-N 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- AFMOTCMSEBITOE-YEPSODPASA-N Gly-Val-Thr Chemical compound NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(O)=O AFMOTCMSEBITOE-YEPSODPASA-N 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- UGTHTQWIQKEDEH-BQBZGAKWSA-N L-alanyl-L-prolylglycine zwitterion Chemical compound C[C@H](N)C(=O)N1CCC[C@H]1C(=O)NCC(O)=O UGTHTQWIQKEDEH-BQBZGAKWSA-N 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 108020002230 Pancreatic Ribonuclease Proteins 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 102000005891 Pancreatic ribonuclease Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010030678 Phosphatidylethanolamine N-Methyltransferase Proteins 0.000 description 1
- KDBHVPXBQADZKY-GUBZILKMSA-N Pro-Pro-Ala Chemical compound OC(=O)[C@H](C)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 KDBHVPXBQADZKY-GUBZILKMSA-N 0.000 description 1
- LEIKGVHQTKHOLM-IUCAKERBSA-N Pro-Pro-Gly Chemical compound OC(=O)CNC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 LEIKGVHQTKHOLM-IUCAKERBSA-N 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000040739 Secretory proteins Human genes 0.000 description 1
- 108091058545 Secretory proteins Proteins 0.000 description 1
- XJDMUQCLVSCRSJ-VZFHVOOUSA-N Ser-Thr-Ala Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C)C(O)=O XJDMUQCLVSCRSJ-VZFHVOOUSA-N 0.000 description 1
- GZYNMZQXFRWDFH-YTWAJWBKSA-N Thr-Arg-Pro Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1CCC[C@@H]1C(=O)O)N)O GZYNMZQXFRWDFH-YTWAJWBKSA-N 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 108010069020 alanyl-prolyl-glycine Proteins 0.000 description 1
- 108010070944 alanylhistidine Proteins 0.000 description 1
- 108010087924 alanylproline Proteins 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- -1 cells Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000005138 cryopreservation Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000012502 diagnostic product Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000006052 feed supplement Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- VPZXBVLAVMBEQI-UHFFFAOYSA-N glycyl-DL-alpha-alanine Natural products OC(=O)C(C)NC(=O)CN VPZXBVLAVMBEQI-UHFFFAOYSA-N 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108010087846 prolyl-prolyl-glycine Proteins 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 239000011534 wash buffer Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57415—Specifically defined cancers of breast
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
- C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Genetics & Genomics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
本发明涉及生物技术领域,特别涉及CA153融合蛋白及其制备方法和CA153检测质控品或校准品。该融合蛋白由HER2信号肽、可溶标签类蛋白和CA153多肽重复结构构成。本发明将高表达的蛋白(HER2)信号肽、便于纯化的标签蛋白与低表达的多肽蛋白(4~10个CA153多肽)融合表达,在不影响CA153的结构与功能下,可以提高CA153的产量和稳定性,该融合蛋白解决了表达量低与稳定性的问题。并使得CA153多肽蛋白可以分泌到上清中,有利于纯化。
Description
技术领域
本发明涉及生物技术领域,特别涉及CA153融合蛋白及其制备方法和CA153检测质控品或校准品。
背景技术
CA15-3蛋白是mucin1基因编码的,别名又叫做Breast carcinoma-associatedantigen DF3、MUC-1、KL-6、PEMT、PUM、PEM、EMA、CD227等,有将近80种异构体,不同组织的CA15-3的氨基酸序列不相同,其糖基化程度也不相同。CA15-3的肽段的分子量在120-225kDa,糖基化后大小在250–1000kDa,分为α链和β链,α链与β链是非共价键结合,CA15-3属于唾液酸化的糖蛋白亚类,又称多态性上皮粘蛋白(PEM)。
正常情况下,PEM只存在于腺体细胞腔的分泌物中,不出现在血循环中。当细胞恶变时,基底细胞膜渗透性增强,PEM可在血清中由CA15-3方法检测出来。CA15-3在乳腺癌患者血清中升高,在乳腺癌初期的敏感性为60%,在乳腺癌晚期的敏感性为80%;同时CA15-3对乳腺癌的疗效观察、预后判断,复发和转移的诊断有重要价值。CA15-3在其他恶性肿瘤中也有一定的阳性率,例如:肺癌、结肠癌、胰腺癌、卵巢癌、子宫颈癌、原发性肝癌等。目前CA15-3已被列为乳腺癌的最重要的特异性标志物。
目前常采用免疫分析法来检测血浆中CA15-3蛋白含量,因此,需使用高质量的校准品作为对照,作为对照的CA15-3蛋白质需要活性高、稳定性好,经过长时间贮存而活性几乎无下降。目前高品质CA15-3蛋白来源于天然提取,但是,由于天然提取的CA15-3来源不稳定,并且,目的蛋白含量低且蛋白结构不均一等原因,严重阻碍CA15-3蛋白校准品等诊断产品的研究开发,因此,需要研发一种可大量生产CA15-3的方法。
发明内容
有鉴于此,本发明提供了CA153融合蛋白及其制备方法和CA153检测质控品或校准品。该融合蛋白解决了表达量低与稳定性的问题。
为了实现上述发明目的,本发明提供以下技术方案:
本发明提供了一种CA153融合蛋白,该融合蛋白由HER2信号肽、可溶标签类蛋白和CA153多肽重复结构构成。
由于单独的CA153多肽表达量太低,本申请选择融合一个表达量相对较高的分泌型蛋白HER2信号肽序列。本技术方案为:构建瞬时表达质粒--细胞培养--细胞转染--收获融合蛋白;构建稳定表达质粒--细胞培养--构建稳定表达细胞株--持续的收获融合蛋白。本发明中利用了本实验室中已经存在的HER2信号肽、GST标签蛋白基因和合成4至10个CA153多肽序列,全长基因序列,将其克隆至瞬时表达质粒和稳定表达质粒中,将质粒转染至CHO细胞中,收获上清中的蛋白。
本发明创新性将降低到CA153重复结构域降低到4-10即可表达,在不影响CA153的结构与功能下,可以提高CA153的产量和稳定性,并使得CA153多肽蛋白可以分泌到上清中,有利于纯化。
作为优选,HER2信号肽位于融合蛋白的N端,可溶标签类蛋白位于HER2信号肽和CA153多肽重复结构之间,CA153多肽重复结构位于融合蛋白的C端。
作为优选,CA153多肽重复结构由4至10个CA153多肽片段组成。
优选地,CA153多肽重复结构由6个CA153多肽片段组成。
在本发明中,CA153多肽片段的氨基酸序列如SEQ ID NO:1所示。
在本发明中,可溶标签类蛋白选自但不限于GST蛋白、Trx蛋白中的一种或两种。
在本发明中,HER2信号肽的氨基酸序列如SEQ ID NO:2所示。
本发明还提供了编码上述融合蛋白的基因。
本发明还提供了一种表达载体,表达载体包含上述基因。
在本发明中,表达载体为哺乳动物细胞常用表达载体如PCMV3,但不限于此。
本发明还提供了一种表达细胞株,表达细胞株包含上述表达载体。
本发明还提供了该融合蛋白的制备方法,包括如下步骤:构建表达载体,细胞培养,构建表达细胞株,收获融合蛋白。
在本发明具体实施例中,该融合蛋白的制备方法包括如下步骤:构建瞬时表达质粒,细胞培养,细胞转染,收获融合蛋白。
在本发明另一具体实施例中,该融合蛋白的制备方法包括如下步骤:构建稳定表达质粒,细胞培养,构建稳定表达细胞株,收获融合蛋白。
本发明还提供了一种CA153检测质控品或校准品,包括上述融合蛋白。
本发明提供了CA153融合蛋白及其制备方法和CA153检测质控品或标准品。该融合蛋白由HER2信号肽、可溶标签类蛋白和CA153多肽重复结构构成。本发明的优点在于:
将高表达的蛋白(HER2)信号肽、便于纯化的标签蛋白与低表达的多肽蛋白(4~10个CA153多肽)融合表达,在不影响CA153的结构与功能下,可以提高CA153的产量和稳定性,该融合蛋白解决了表达量低与稳定性的问题。并使得CA153多肽蛋白可以分泌到上清中,有利于纯化。
附图说明
图1为构建瞬转体系中PCMV3质粒图;
图2为瞬转体系中蛋白的表达和纯化:SDS-PAGE结果中,SY是细胞上清,LC是纯化流穿;JL是纯化后样品还原电泳,JL非是纯化后样品非还原电泳。
具体实施方式
本发明公开了CA153融合蛋白及其制备方法和CA153检测质控品或校准品,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明的方法及应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述的方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
CA153多肽序列如SEQ ID NO:1所示:APDTRPAPGSTAPPAHGVTS
HER2蛋白信号肽的氨基酸序列如SEQ ID NO:2所示:MELAALCRWGLLLALLPPGAAS
本发明提供的CA153融合蛋白及其制备方法和CA153检测质控品或校准品中所用质粒、细胞、试剂或仪器均可由市场购得。
下面结合实施例,进一步阐述本发明:
实施例1用293细胞构建瞬时表达融合蛋白的体系
(1)构建含目的基因质粒
根据实验需求选用实验室带有HER2信号肽的PCMV3质粒作为骨架,将CA153合成目的基因片段插入多克隆位点。
表1 GST标签扩展PCR体系
表2 CA153多肽扩增PCR体系
表3 PCR程序
胶回收:
将DNA片段跑1%的DNA琼脂胶,而后用回收试剂盒进行回收,而后进行PCR。
搭桥PCR:
引物信息如下,经过PCR后,胶回收,而后进行同源重组。
表4 GST和CA153多肽搭桥PCR体系
表5载体酶切体系
体系 | 体积 |
10*CUTSMARTbuffer | 4μL |
XbaI | 2μL |
NotI | 2μL |
质粒 | 2000ng |
ddH2O | Upto40μL |
37℃PCR仪中酶切2h,跑DNA胶胶回收后进行同源重组。
表6同源重组体系
50℃同源重组2h,连接产物取出冰浴10min后转化。
质粒转化
1)将感受态细胞从-80℃冰箱中取出,置于冰上使其化开。取1.5mL的EP管,冰浴。
2)取100μL的感受态细胞于1.5mL EP管中,加入10μL的酶连接液,混合后冰浴半小时。其阴性对照为0.5μL的酶切回收液。
3)42℃水浴锅中热激90sec,冰浴2min。
4)在超净台中向EP管中加入1mL的无抗LB培养基,于37℃,220rpm摇床中摇1h孵育。
5)室温4000rpm,离心5min。
6)在超净台中弃上清,留100μL上清,将菌混匀后涂平板(平板为含卡那霉素的LB平板)。
7)37℃培养箱中放置过夜,约14小时后即可看到单克隆菌落。
8)测序验证
序列正确后保存质粒并表达该蛋白(菌株为DH5α)
1)接菌,早上挑取单克隆至5mL的含卡那霉素的LB培养基中,在37℃摇床中以260rpm摇菌12h。将5mL的菌液接菌于1L三角摇瓶(含300μL的卡那霉素LB培养基)中,在37℃摇床中以260rpm过夜摇菌,约16-18h。
2)收菌,4℃,4000rpm离心15min,弃上清。
3)细胞悬浮,加入8mL的4℃的RES溶液(含Rnase A),用涡旋仪剧烈震荡,使菌液充分混匀。将混合菌液移至50mLBD管中。
4)细胞裂解,加入8mL的LYS溶液,轻轻的上下颠倒5-10次,室温静置5min。
5)加入8mL的NEU溶液,上下颠倒混匀,此时有大量的白色絮状沉淀生成,室温静置5min。
6)离心,4℃,4000rpm离心30min。离心的同时用12mL的EQU溶液平衡纯化柱(内嵌有过滤管),操作时用移液管在过滤管的管口圆圈上液,从而保证过滤管处处湿润。
7)纯化柱平衡后,将上步离心所得的上清缓慢的在过滤管的管口圆圈上液,要保证不要将上清不经过滤就到纯化柱里。
8)加入5mL的EQU溶液洗涤,操作时同样用移液管在过滤管的管口圆圈上液。丢弃纯化柱内的过滤管。
9)加入8mL的washbuffer,洗涤纯化柱。
10)加入5mL的ELU溶液洗脱纯化柱吸附的DNA质粒,用15mL的BD管收集洗脱液。
11)向洗脱液中加入3.5mL的异丙醇,混匀后室温静置2min。
12)用30mL注射器将11)步中的混合液缓慢的过NucleoBondFinalizer蓝色滤头,过滤液以滴滴滴落为佳,弃过滤液。
13)配制70%-80%的乙醇,类似上步,用30mL注射器将2mL的乙醇液缓慢的过蓝色滤头,弃流出液。
14)用30mL注射器将空气单方向吹过蓝色滤头,至少吹过3次,使滤头内乙醇蒸发干净。
15)用1mL注射器将55℃的ddH2O缓慢的洗脱滤头,收集洗脱液,测DNA质粒浓度。
(2)融合蛋白瞬时表达
细胞培养/细胞传代/细胞冻存/细胞转染(90cm培养皿为例)
1)细胞复苏:将于液氮中保存的细胞取出后快速放置于37℃水浴锅中,使细胞液体快速融化,融化后直接将细胞液加入30mL SMM-293无血清培养基的125mL三角瓶中(Corning),置于37℃5%CO2100rpm/min的细胞培养摇床,注意融化后的细胞液不进行离心处理。
2)细胞培养:将细胞活率大于95%的接种于含30mL相应的无血清培养基的125mL三角瓶中(Corning,货号431144),置于37℃5%CO2100rpm/min的细胞培养摇床。密度控制在0.5×10^6cells/mL-4×10^6cells/mL,传代放大时使用稀释传代的方法,不使用离心重悬方法。
PEI转染:将HEK293F细胞以5×105cell/mL接种到揺瓶中,72h后细胞密度长到30-40×105cell/mL,活率大于90%可进行转染。转染当天将细胞稀释到30×105cell/mL,使用PEI将提取质粒转入HEK293F细胞,将转染试剂PEI和质粒DNA按照设计的比例用稀释液进行稀释,后混匀静置,逐滴加入细胞培养液中,转染后第1、3和5天进行补料计数,观察细胞生长状态,当细胞活率低于50%时收获细胞。使用Countstar进行细胞计数,检测活细胞密度和细胞活率。
(3)纯化目的蛋白
收集的293细胞上清,使用0.02M PBS ph7.4进行浓缩洗滤置换缓冲液,然后上样已平衡过的GST亲和层析填料,最后使用10mM GSH一步解离目的蛋白,并进行电泳分析纯度。如图2。
(4)重组蛋白效价考察
使用罗氏试剂盒上机检测抗原(抗原浓度1.62mg/ml)效价如下,取平均值13772U/ml。
表7
样品编号 | 蛋白检测值U/ml | 发光值 | 换算效价值U/ml |
100* | 154.6 | 62930 | 15460 |
200* | 71.28 | 30687 | 14356 |
1000* | 11.60 | 6035 | 11600 |
PBS(空白对照) | 1.0 | 1051 | / |
试验例本申请融合蛋白与HIS-CA153融合蛋白表达量的比较
采用与实施例1相同的方法进行构建HER2-CA153-HIS融合蛋白表达体系和纯化,HER2-GST-CA153和HER2-CA153-HIS融合蛋白表达情况如下所示:
表8融合蛋白表达情况
融合蛋白 | 表达情况 | 纯化结果 |
HER2-GST-CA153 | 945U/ml | 8500U/mg |
HER2-CA153-HIS | 646U/ml | 1900U/mg |
可见,HER2-GST-CA153融合蛋白表达水平及应用性是强于高表达蛋白HER2-CA153-HIS融合蛋白的。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
序列表
<110> 郑州伊美诺生物技术有限公司
<120> CA153融合蛋白及其制备方法和CA153检测质控品或校准品
<130> MP21011896
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 20
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 1
Ala Pro Asp Thr Arg Pro Ala Pro Gly Ser Thr Ala Pro Pro Ala His
1 5 10 15
Gly Val Thr Ser
20
<210> 2
<211> 22
<212> PRT
<213> 人工序列(Artificial Sequence)
<400> 2
Met Glu Leu Ala Ala Leu Cys Arg Trp Gly Leu Leu Leu Ala Leu Leu
1 5 10 15
Pro Pro Gly Ala Ala Ser
20
Claims (7)
1.一种CA153融合蛋白,其特征在于,所述融合蛋白由HER2信号肽、可溶标签类蛋白和CA153多肽重复结构构成;
所述HER2信号肽位于融合蛋白的N端,所述可溶标签类蛋白位于HER2信号肽和CA153多肽重复结构域之间,所述CA153多肽重复结构位于融合蛋白的C端;
所述CA153多肽重复结构由4至10个CA153多肽片段组成;所述CA153多肽片段的氨基酸序列如SEQ ID NO:1所示;
所述HER2信号肽的氨基酸序列如SEQ ID NO:2所示。
2.根据权利要求1所述的融合蛋白,其特征在于,所述可溶标签类蛋白选自但不限于GST蛋白、Trx蛋白中的一种或两种。
3.编码权利要求1或2所述融合蛋白的基因。
4.一种表达载体,其特征在于,所述表达载体包含权利要求3所述的基因。
5.一种表达细胞株,其特征在于,所述表达细胞株包含权利要求4所述的表达载体。
6.权利要求1或2所述融合蛋白的制备方法,其特征在于,包括如下步骤:构建表达载体,细胞培养,构建表达细胞株,收获融合蛋白。
7.一种CA153检测质控品或校准品,其特征在于,包括权利要求1或2所述的融合蛋白。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110929276.8A CN113480666B (zh) | 2021-08-13 | 2021-08-13 | Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110929276.8A CN113480666B (zh) | 2021-08-13 | 2021-08-13 | Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113480666A CN113480666A (zh) | 2021-10-08 |
CN113480666B true CN113480666B (zh) | 2024-01-26 |
Family
ID=77946454
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202110929276.8A Active CN113480666B (zh) | 2021-08-13 | 2021-08-13 | Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113480666B (zh) |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101412749A (zh) * | 2008-10-29 | 2009-04-22 | 台桂香 | Muc1串联重复序列多肽及其制备工艺以及作为抗肿瘤药物的应用 |
CN109963585A (zh) * | 2016-09-21 | 2019-07-02 | 阿尔勒治疗公司 | 包括细胞穿透肽、多表位和tlr肽激动剂的用于治疗癌症的融合物 |
CN111548422A (zh) * | 2020-05-26 | 2020-08-18 | 郑州伊美诺生物技术有限公司 | 一种人促甲状腺激素受体融合蛋白及其制备方法和应用 |
CN112143733A (zh) * | 2020-09-30 | 2020-12-29 | 南京基蛋生物医药有限公司 | Ca15-3编码基因、ca15-3蛋白及其制备方法和应用 |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0321614D0 (en) * | 2003-09-15 | 2003-10-15 | Glaxo Group Ltd | Vaccines |
FR2899902B1 (fr) * | 2006-04-18 | 2012-01-27 | Agronomique Inst Nat Rech | Proteines de fusion proteine n d'un virus de la famille des paramyxoviridae-proteine d'interet et leurs utilisations pour la vaccination et la vectorisation intra-cellulaire. |
JP2011502520A (ja) * | 2007-11-09 | 2011-01-27 | アナフォア インコーポレイテッド | 疾患治療のためのマンノース結合レクチンの融合タンパク質 |
FR2950350B1 (fr) * | 2009-09-24 | 2013-12-13 | Centre Nat Rech Scient | Nouveaux polynucleotides et polypeptides chimeriques permettant la secretion d'un polypeptide d'interet en association avec des exosomes et leurs utilisations |
EP2545071A2 (en) * | 2010-03-09 | 2013-01-16 | Maksyutov, Amir | Polyepitope constructs and methods for their preparation and use |
-
2021
- 2021-08-13 CN CN202110929276.8A patent/CN113480666B/zh active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101412749A (zh) * | 2008-10-29 | 2009-04-22 | 台桂香 | Muc1串联重复序列多肽及其制备工艺以及作为抗肿瘤药物的应用 |
CN109963585A (zh) * | 2016-09-21 | 2019-07-02 | 阿尔勒治疗公司 | 包括细胞穿透肽、多表位和tlr肽激动剂的用于治疗癌症的融合物 |
CN111548422A (zh) * | 2020-05-26 | 2020-08-18 | 郑州伊美诺生物技术有限公司 | 一种人促甲状腺激素受体融合蛋白及其制备方法和应用 |
CN112143733A (zh) * | 2020-09-30 | 2020-12-29 | 南京基蛋生物医药有限公司 | Ca15-3编码基因、ca15-3蛋白及其制备方法和应用 |
Also Published As
Publication number | Publication date |
---|---|
CN113480666A (zh) | 2021-10-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN108265056A (zh) | 一种重组户尘螨1类变应原蛋白及其制备方法和应用 | |
CN108660128B (zh) | 一种紫花苜蓿萜烯合成酶、其编码基因、载体、多克隆抗体及其应用 | |
CN113736763B (zh) | 黑芥子酶Rmyr及其在制备萝卜硫素、莱菔素中的应用 | |
CN114672447B (zh) | 一种具有自絮凝能力的菌株及其制备方法与应用 | |
CA2609473A1 (en) | A recombinant method for production of an erythropoiesis stimulating protein | |
CN113480666B (zh) | Ca153融合蛋白及其制备方法和ca153检测质控品或校准品 | |
CN109957003B (zh) | 一种稳定的saa突变体及其在疾病检测中的应用 | |
CN114573672B (zh) | 西瓜苦味物质葫芦素e的转运蛋白及其应用 | |
CN115960227A (zh) | 一种抗人msh2的单克隆抗体及其制备方法和应用 | |
CN109320601A (zh) | 重组igf-1蛋白和高效表达及其在促细胞增殖方面的用途 | |
CN112646044B (zh) | TFF2-Fc融合蛋白及其高效表达生产方法 | |
CN115029330A (zh) | 一种野生型impdh ii蛋白的表达纯化方法 | |
CN111575314A (zh) | 尿激酶受体稳定突变体suPARcc在真核胞外蛋白表达中的应用 | |
CN108753819B (zh) | 真核表达载体、真核表达系统、二者的制备方法和应用及gdf11蛋白 | |
CN112142848A (zh) | 一种重组人胰岛素及其纯化制备方法 | |
CN114409800B (zh) | 制备重组胱抑素c的方法 | |
CN112646837A (zh) | 重组人脂联素表达载体、载体构建方法及表达方法 | |
CN110607304A (zh) | 肝细胞生长因子的重组表达方法 | |
CN113637675B (zh) | 一种人血清白蛋白的生产方法、核苷酸序列、表达载体及表达系统 | |
CN113564185B (zh) | 一种碱性磷酸酶基因及其cho稳定细胞株和alp制备方法 | |
CN116790616B (zh) | 编码sCXCL16的基因及表达载体、制备方法和应用 | |
CN105524942A (zh) | 一种表达载体及胰岛素样生长因子结合蛋白3的表达方法 | |
WO2023045470A1 (zh) | 一种重组促甲状腺激素受体蛋白、制备方法及应用 | |
CN115785227A (zh) | 一种外源表达蛋白的信号标志物、外源表达蛋白及其制备方法 | |
CN116083475A (zh) | 一种在毕赤酵母中表达人igf-1或其类似物lr3 igf-1的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |